NEW YORK (GenomeWeb News) – Following Illumina's purchase of Advanced Liquid Logic in July, GenMark has liquidated its preferred stock investment in ALL but retained its license to the firm's digital microfluidics technology, GenMark said in its Form 10-Q filed with the US Securities and Exchange Commission this week.
GenMark received a cash payment of about $2.4 million, comprising a $1 million return of investment and a $1.4 million realized gain to be recorded in the third quarter.
Quest Diagnostics said that it and Transgenomic entered into a licensing deal, resulting in a genetic test for variants in CYP450 genes. The genes influence the CYP450 enzyme system, which affects the metabolism of opioids and other medications.
The test, launched this week by Quest, is based in part on gene variants owned by Transgenomic. Quest developed, validated and offers the test service through its Nichols Institute facility in San Juan Capistrano, Calif.
Cancer Genetics missed making an initial capital contribution of $1.0 million as required for its joint venture with Mayo Foundation for Medical Education and Research, the Rutherford, N.J.-based firm said in its Form 10-Q. As part of its agreement with Mayo, which resulted in the formation of a company called OncoSpire, Cancer Genetics was required to make an initial $1.0 million contribution by July 31. "[W]hile no assurances can be given, we believe Mayo will not declare a default and will extend the date for this payout," Cancer Genetics said in its document. It added that it is negotiating an amendment to its agreement with Mayo to fund the JV and extend the dates and its payment schedule.
PerkinElmer, its Caliper business, Xenogen, and Stanford University's board sued Bruker and its BioSpin subsidiary, Bruker said this week in its Form 10-Q. In the lawsuit filed in US District Court, California Northern District in April, the plaintiffs allege breach of an agreement assumed by Bruker BioSpin when it acquired Carestream Health's X-ray and optical imaging business in October 2012. Bruker and the BioSpin business are also alleged to have infringed certain patents held or licensed to the plaintiffs. PerkinElmer and the other plaintiffs seek monetary damages and injunctive relief with respect to the infringement claims. Bruker said it will "vigorously" defend itself.
Waters has acquired all the outstanding stock of Scarabaeus Mess-und Prodktionstechnik, a Germany-based manufacturer of rheometers for the rubber and elastomer markets, Waters said in its Form 10-Q last week. It paid approximately $4 million in cash in the deal.
Hologic bought certain assets related to SenoRx's Contura brachytherapy device for $2.4 million, the company said in its Form 10-Q. SenoRx develops breast cancer diagnostic and treatment devices.
Biospecimen firm Sanguine BioSciences has inked a distribution partnership with AMS Biotechnology making Sanguine's products and services available to researchers in Europe. Terms of the deal were not disclosed. Valencia, Calif.-based Sanguine announced the completion of a seed funding round in February.
Quanterix said that its recently launched Simoa HD-1 Analyzer uses a "smart consumable" designed and manufactured by Sony DADC BioSciences. It is the first consumable whose assay technology is based on optical disc formats by Sony DADC, Quanterix said.
Northeastern University's Marine Science Center will house the Ocean Genome Legacy Center of New England Biolabs, a publicly accessible biorepository of DNA samples from ocean species. The collection of samples will move to the Marine Science Center later this year and will continue to be used to elucidate genomic information that could result in cures for diseases, approaches to protect the environment, and approaches to improve the sustainability of global food and energy supplies. New England Biolabs and private donors are providing financial support for the center.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.